HIGH-SENSITIVITY TROPONIN I CONCENTRATIONS IN TYPE 2 DIABETES PATIENTS: ASSOCIATION WITH AGE AND GENDER
Main Article Content
Abstract
Objective: This study was conducted to describe the distribution characteristics of high-sensitivity troponin I levels according to age and sex in two groups of patients with and without type 2 diabetes, thereby assessing the role of high-sensitivity troponin I in early cardiovascular complication screening and prognosis.
Methods: A case-control study was conducted on 372 patients aged ≥ 18 years who visited or were admitted to Long Thanh regional General Hospital from December 2024 to June 2025, including 183 patients with type 2 diabetes and 189 patients without type 2 diabetes. Patients with a history of or current cardiovascular disease were excluded.
Results: The study showed that high-sensitivity troponin I levels were significantly higher in the type 2 diabetes group compared to the non-type 2 diabetes group. The differences were statistically significant with respect to age and sex.
Conclusion: Measurement of high-sensitivity troponin I is useful for early detection of cardiovascular risk in type 2 diabetes patients, even before clinical manifestations appear. However, high-sensitivity troponin I thresholds should be adjusted according to age and sex when assessing cardiovascular risk.
Article Details
Keywords
Type 2 diabetes, hs-TnI, cardiovascular risk.
References
[2] Vinod Mahato R, Gyawali P, Raut P.P et al. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycated haemoglobin as a dual biomarker. Biomedical Research, 2011, 22 (3): 375-380.
[3] Song T, Lan Y et al. Prognostic value of high-sensitivity cardiac troponin for major adverse cardiovascular events in patients with diabetes: A systematic review and meta-analysis. PeerJ, 2023, 11: e16376. doi: 10.7717/peerj.16376.
[4] Hallén J, Johansen O.E, Birkeland K.I et al. Determinants and prognostic implications of cardiac troponin T measured by a sensitive assay in type 2 diabetes mellitus. Cardiovascular Diabetology, 2010, 9: 52. doi: 10.1186/1475-2840-9-52.
[5] Trương Thị Giang, Đỗ Ánh Dương, Lâm Vĩnh Niên. Khảo sát nồng độ troponin I siêu nhạy trên bệnh nhân đái tháo đường type 2. Tạp chí Y học Việt Nam, 2022, 519 (10): 377-384.
[6] Huỳnh Lê Thái Bảo, Nguyễn Sinh Huy và cộng sự. Một số yếu tố nguy cơ tim mạch theo mục tiêu khuyến cáo điều trị của ESC- EASD 2019 ở bệnh nhân đái tháo đường type 2 điều trị ngoại trú tại Trung tâm Y tế huyện Cư Jut, Đắk Nông năm 2020. Tạp chí Nội tiết và Đái tháo đường, 2021, 44: 25-32. doi: 10.47122/vjde.2020.44.4.
[7] Lâm Vĩnh Niên, Trương Thị Giang, Nguyễn Thanh Trầm, Nguyễn Trần Thu Trang. Nồng độ troponin I siêu nhạy (hs-TnI) ở người bệnh đái tháo đường type 2 có tăng lipid máu hỗn hợp. Tạp chí Y học thành phố Hồ Chí Minh, 2024, 27 (3): 120-125. doi: 10.32895/hcjm.m.2024.03.17.
[8] Nguyễn Thanh Vân, Kha Đắc Lượng, Đường Thị Hồng Diệp. Mô tả nồng độ hs troponin I trên bệnh nhân hội chứng chuyển hóa và các yếu tố liên quan. Tạp chí Y học Việt Nam, 2025, 549 (1): 120-123. doi: 10.51298/vmj.v549i1.13531.
[9] American Diabetes Association. Standards of medical care in diabetes - 2023. Diabetes Care, 2023, 43 (1): 1-232.
[10] Shahid M.H, Ali N, Ratnala M et al. Prognostic value of high-sensitivity troponin in predicting long-term cardiovascular outcomes in patients with type 2 diabetes: A systematic review. Cureus, 2025, 17 (5): e83925. doi: 10.7759/cureus.83925.
[11] Cavender M.A, White W.B, Jarolim P et al. Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial (examination of cardiovascular outcomes with Alogliptin versus standard of care). Circulation, 2017, 135 (20): 1911-1921. doi: 10.1161/circulationaha.116.024632.
[12] Yiu K.H, Lau K.K, Zhao C.T et al. Predictive value of high-sensitivity troponin-I for future adverse cardiovascular outcome in stable patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2014, 13: 63. doi: 10.1186/1475-2840-13-63.